New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme.
Manisha SinghDivya JindalVinayak AgarwalDeepanshi PathakMansi SharmaPranav PanchamShalini Mani RachanaPublished in: Exploration of targeted anti-tumor therapy (2022)
Glioblastoma multiforme (GBM) is known as the most aggressive and prevalent brain tumor with a high mortality rate. It is reported in people who are as young as 10 years old to as old as over 70 years old, exhibiting inter and intra tumor heterogeneity. There are several genomic and proteomic investigations that have been performed to find the unexplored potential targets of the drug against GBM. Therefore, certain effective targets have been taken to further validate the studies embarking on the robustness in the field of medicinal chemistry followed by testing in clinical trials. Also, The Cancer Genome Atlas (TCGA) project has identified certain overexpressed targets involved in the pathogenesis of GBM in three major pathways, i.e., tumor protein 53 (p53), retinoblastoma (RB), and receptor tyrosine kinase (RTK)/rat sarcoma virus (Ras)/phosphoinositide 3-kinase (PI3K) pathways. This review focuses on the compilation of recent developments in the fight against GBM thus, directing future research into the elucidation of pathogenesis and potential cure for GBM. Also, it highlights the potential biomarkers that have undergone extensive research and have promising prognostic and predictive values. Additionally, this manuscript analyses the advent of gene therapy and immunotherapy, unlocking the way to consider treatment approaches other than, or in addition to, conventional chemo-radiation therapies. This review study encompasses all the relevant research studies associated with the pathophysiology, occurrence, diagnostic tools, and therapeutic intervention for GBM. It highlights the evolution of various therapeutic perspectives against GBM from the most conventional form of radiotherapy to the recent advancement of gene/cell/immune therapy. Further, the review focuses on various targeted therapies for GBM including chemotherapy sensitization, radiotherapy, nanoparticles based, immunotherapy, cell therapy, and gene therapy which would offer a comprehensive account for exploring several facets related to GBM prognostics.
Keyphrases
- gene therapy
- cell therapy
- tyrosine kinase
- clinical trial
- drug delivery
- locally advanced
- single cell
- randomized controlled trial
- early stage
- radiation therapy
- stem cells
- epidermal growth factor receptor
- mesenchymal stem cells
- emergency department
- dna methylation
- genome wide
- squamous cell carcinoma
- photodynamic therapy
- copy number
- papillary thyroid
- bone marrow
- protein kinase
- coronary artery disease
- current status
- electronic health record
- open label
- binding protein
- drug release
- placebo controlled
- phase iii